New cell therapy trial offers hope for kids with untreatable autoimmune diseases
NCT ID NCT07439029
Summary
This early-stage study is testing a new cell therapy called YTS109 in children with severe autoimmune diseases that have not improved with standard treatments. About 12 children, aged 5 to 18, will receive a single infusion of these specially engineered cells, which are designed to target and remove harmful immune cells. The main goals are to check if the treatment is safe and to see if it shows any early signs of helping control these difficult diseases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA ASSOCIATED VASCULITIS (AAV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Fudan University
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.